Wine is one of the most chemically complex liquids on Earth. Our technology can identify the chemical signatures of individual bottles and can determine if they are in some way different from what they are expected to be. These suspect bottles are most likely faulty, fake, or adulterated. Our through-bottle analyses means no products need to be opened (and wasted) for testing, which is particularly valuable for those trading in fine or rare bottles or those requiring testing on a large number of products.
Whisky and spirits at all tiers of the market are subject to adulteration and counterfeiting. A 2018 study found that one third of rare Scotch whiskies tested were fakes, while researchers at the University of Manchester have found “own brand” and more affordable commercial spirits to be the most likely targets for counterfeiters. This adulteration not only deceives the consumer, but is also potentially dangerous. Our technology can identify unusual bottles of spirits as well as elevated levels of methanol, even when within the legal limits.
According to various trails and investigations in the EU, an estimated 60% of the oil sold as Extra Virgin Olive Oil between 1993 and 2013 may be in some way fraudulent, whether that be through fake denominations of origin, misleading or false labeling, or the inclusion of non-olive oils in the mixture. Our technology can discriminate between EVOO and other oils in concentrations as low as 1%, making it possible to detect fraud and adulteration in each bottle.
Honey is by definition a totally natural product and yet much of the honey on the market today has been heavily processed and adulterated using sugar syrups such as glucose, fructose, and corn syrup. Of particular risk are rarer, more valuable honeys, including New Zealand’s Manuka honey; half of all Manuka-labeled products sold in the UK may be fraudulent. Our technology can distinguish between jars of authentic honey and those that have been adulterated or faked.
We are currently researching the pharmaceutical and biomedical applications of our technology. Most prominently this includes a recent partnership with Oxford University to study degradation of particular compounds in the COVID-19 vaccine over time. This is the first of many injectables and other pharmaceutical liquids to which our solutions can and will be applied.
Companies interested in becoming early adopters of VeriVin’s technology solutions while securing a substantial discount on any future purchase of the system and/or service can now become one of our Early Development Partners. VeriVin is happy to collaborate with companies of any size and from any industry interested in through-barrier analysis. You bring the sample, we bring our device and expertise.